Search company, investor...
BioLife Solutions company logo

BioLife Solutions

Founded Year




Market Cap


Stock Price




About BioLife Solutions

BioLife Solutions (NASDAQ: BLFS) provides biopreservation tools for cells, tissues, and organs that aims to facilitate basic and applied research and the commercialization of new therapies by maintaining the health and function of biologic source material and finished products during manufacturing, distribution, and clinical administration.

Headquarters Location

3303 Monte Villa Parkway Suite 310

Bothell, Washington, 98021,

United States


Missing: BioLife Solutions's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioLife Solutions's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

BioLife Solutions Patents

BioLife Solutions has filed 24 patents.

The 3 most popular patent topics include:

  • Cooling technology
  • Cryogenics
  • Industrial gases
patents chart

Application Date

Grant Date


Related Topics




Bacteriology, Microbiology, Environmental soil science, Disinfectants, Carboxylic acids


Application Date


Grant Date



Related Topics

Bacteriology, Microbiology, Environmental soil science, Disinfectants, Carboxylic acids



Latest BioLife Solutions News

BioLife : Shareholder Director Nominations - Form 8-K

May 19, 2023

05/19/2023 | 04:35pm EDT Message : Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 BIOLIFE SOLUTIONS, INC. Delaware incorporation) Registrant's telephone number, including area code: (425) 402-1400 N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class BioLife Solutions, Inc. Common Stock BLFS NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. The Board of Directors of BioLife Solutions, Inc., a Delaware corporation, (the "Company") determined that the Company's 2023 Annual Meeting of Stockholders (the "Annual Meeting") will be held on July 21, 2023. It is expected that the Annual Meeting will be held virtually on the internet, but the time and location of the Annual Meeting will be as set forth in the Company's definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission ("SEC"). Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of the Company's 2022 annual meeting of stockholders held on June 9, 2022, the Company has set a new deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), for inclusion in the Company's proxy statement for the Annual Meeting. Pursuant to the Company's Amended and Restated Bylaws (the "Bylaws"), stockholders seeking to bring business before the Annual Meeting or to nominate candidates for election as directors at the Annual Meeting must deliver such proposals or nominations to the principal executive offices of the Company, at 3303 Monte Villa Parkway, Suite 310, Bothell, Washington 98021, Attention: Secretary, not later than June 6, 2023. Any stockholder proposal or director nomination must comply with the processes and procedures outlined in the Bylaws and must also comply with the requirements of Delaware law and the rules and regulations promulgated by the SEC, as applicable. A copy of the Company's Bylaws can be found on the Company's website at SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioLife Solutions, Inc.

BioLife Solutions Frequently Asked Questions (FAQ)

  • When was BioLife Solutions founded?

    BioLife Solutions was founded in 1987.

  • Where is BioLife Solutions's headquarters?

    BioLife Solutions's headquarters is located at 3303 Monte Villa Parkway, Bothell.

  • What is BioLife Solutions's latest funding round?

    BioLife Solutions's latest funding round is PIPE.

  • Who are the investors of BioLife Solutions?

    Investors of BioLife Solutions include Casdin Capital and Cryomedical Sciences.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.